Naserifar Mahshid, Ataei Mahshid, Behzadian Nadia, Mohammadpour Amir Hooshang, Dastani Mostafa, Sahebkar Amirhossein, Hosseinjani Hesamoddin
Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Int J Vasc Med. 2020 Sep 19;2020:4592190. doi: 10.1155/2020/4592190. eCollection 2020.
Coronary slow flow (CSF) is an important angiographic entity that is characterized by delayed opacification of coronary arteries in the absence of epicardial occlusive disease. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase. Elevated levels of ADMA cause the induction of endothelial dysfunction and thus promote atherosclerosis. This study was aimed at determining the role of ADMA in the development of CSF. One hundred twenty-nine subjects who fulfilled the inclusion criteria were enrolled in this study. According to coronary angiography results, these subjects were divided into five groups. The serum concentration of ADMA was measured in these subjects. In this study, there was no significant correlation between serum concentrations of ADMA and mean corrected TIMI frame count (CTFC) ( > 0.05). However, the ADMA level was significantly correlated with CTFC in the left anterior descending (LAD) coronary artery in patients with CSF ( = -0.381, = 0.045). Also, plasma ADMA levels were significantly higher in patients with CSF and without CAD compared to patients without CSF and with CAD (50-90%) ( = 0.034). Besides, serum concentrations of ADMA were significantly higher in subjects with BMI < 25 kg/m compared with those having BMI > 30 kg/m ( = 0.003). It was also shown that the levels of ADMA were significantly higher in subjects with age as a cardiovascular risk factor compared with those without this risk factor ( = 0.024). Further studies with larger population sizes are needed to confirm the present findings on the association between the serum concentrations of ADMA and CSF.
冠状动脉慢血流（CSF）是一种重要的血管造影表现，其特征是在没有心外膜闭塞性疾病的情况下冠状动脉造影剂显影延迟。不对称二甲基精氨酸（ADMA）是一氧化氮合酶的内源性抑制剂。ADMA水平升高会导致内皮功能障碍，从而促进动脉粥样硬化。本研究旨在确定ADMA在CSF发生发展中的作用。129名符合纳入标准的受试者参与了本研究。根据冠状动脉造影结果，这些受试者被分为五组。测定了这些受试者的血清ADMA浓度。在本研究中，ADMA血清浓度与平均校正TIMI帧数（CTFC）之间无显著相关性（>0.05）。然而，在CSF患者中，ADMA水平与左前降支（LAD）冠状动脉的CTFC显著相关（=-0.381，=0.045）。此外，与无CSF且有CAD（50-90%）的患者相比，有CSF且无CAD的患者血浆ADMA水平显著更高（=0.034）。此外，BMI<25kg/m的受试者血清ADMA浓度显著高于BMI>30kg/m的受试者（=0.003）。研究还表明，有年龄作为心血管危险因素的受试者的ADMA水平显著高于无此危险因素的受试者（=0.024）。需要进一步开展更大规模人群的研究来证实目前关于ADMA血清浓度与CSF之间关联的研究结果。
